Published in J Neurol on January 01, 2015
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord (2000) 15.38
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Peripheral neuropathies and anti-glycolipid antibodies. Brain (2002) 3.04
A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol (1988) 2.12
Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients. Mayo Clin Proc (2009) 1.88
Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology (2010) 1.80
Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features. Neurology (2010) 1.72
Dangerous small B-cell clones. Blood (2006) 1.70
An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy. Neurology (2001) 1.64
Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes. Neurology (1990) 1.61
Lymphoproliferative disorders and motor neuron disease: an update. Neurology (1997) 1.54
Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin. N Engl J Med (1980) 1.54
Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma. AIDS Read (2004) 1.40
Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol (2011) 1.25
ALS syndrome in patients with HIV-1 infection. J Neurol Sci (2005) 1.14
Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment. Ann Neurol (2000) 1.12
Quantification of reverse transcriptase in ALS and elimination of a novel retroviral candidate. Neurology (2008) 1.12
Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness. Brain (2003) 1.10
Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA. J Neurol Sci (2005) 1.06
Pathogenesis and therapy of neuropathies associated with monoclonal gammopathies. Ann Neurol (1995) 1.02
Multifocal motor neuropathy: the diagnostic spectrum and response to treatment. Neurology (2007) 0.98
Antibodies to heteromeric glycolipid complexes in multifocal motor neuropathy. Eur J Neurol (2012) 0.95
An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst (2011) 0.92
Progressive muscular atrophy and other lower motor neuron syndromes of adults. Muscle Nerve (2010) 0.92
Retrovirus-induced motor neuron disease of mice: molecular basis of neurotropism and paralysis. Adv Neurol (1991) 0.91
Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study. Neurology (2010) 0.90
Pathogenesis and Treatment of Anti-MAG Neuropathy. Curr Treat Options Neurol (2010) 0.87
Motor neuron disease and plasma cell dyscrasia. Neurology (1986) 0.86
Quantitative analysis of monoclonal immunoglobulins in serum of patients with amyotrophic lateral sclerosis. J Neurol Sci (1991) 0.83
Antiglycolipid antibodies, immunoglobulins and paraproteins in motor neuron disease: a population based case-control study. J Neurol Sci (1993) 0.83
Motor neuron diseases and amyotrophic lateral sclerosis: GM1 antibodies and paraproteinemia. Neurology (1993) 0.80
IgM paraproteinemia in a patient with primary lateral sclerosis. Neuromuscul Disord (1999) 0.79
[Paraproteinemia and motor neuron disease]. Rinsho Shinkeigaku (1992) 0.79
Motor neuron disease and monoclonal gammopathy. Eur Neurol (1995) 0.78
Multifocal motor neuropathy mimicking motor neuron disease: nine cases. J Neurol Sci (1999) 0.77
Antiganglioside antibodies in polyneuropathy associated with monoclonal gammopathy. Neurology (2001) 0.76
Adult-onset primary lateral sclerosis is not associated with mutations in the ALS2 gene. Neurology (2007) 0.76
Chronic motor axonal neuropathy. J Peripher Nerv Syst (2011) 0.75
Antibodies against peripheral myelin glycolipids in people with HIV infection. Immunol Cell Biol (1998) 0.75
Gammopathy with proximal motor axonopathy simulating motor neuron disease. Neurology (1986) 0.75
Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98
Multiple common variants for celiac disease influencing immune gene expression. Nat Genet (2010) 6.90
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol (2008) 6.06
Genome-wide association study identifies 19p13.3 (UNC13A) and 9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet (2009) 4.38
Trans-eQTLs reveal that independent genetic variants associated with a complex phenotype converge on intermediate genes, with a major role for the HLA. PLoS Genet (2011) 3.65
Chromosome 9p21 in sporadic amyotrophic lateral sclerosis in the UK and seven other countries: a genome-wide association study. Lancet Neurol (2010) 3.61
Common variants in 22 loci are associated with QRS duration and cardiac ventricular conduction. Nat Genet (2010) 3.55
Euthanasia and physician-assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands. N Engl J Med (2002) 3.51
Aging effects on DNA methylation modules in human brain and blood tissue. Genome Biol (2012) 3.05
ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study. Lancet Neurol (2007) 2.80
A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol (2007) 2.73
EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med (2012) 2.65
Genetic variation in DPP6 is associated with susceptibility to amyotrophic lateral sclerosis. Nat Genet (2007) 2.63
Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain (2008) 2.60
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. Nat Genet (2010) 2.56
Copy-number variation in sporadic amyotrophic lateral sclerosis: a genome-wide screen. Lancet Neurol (2008) 2.54
Controversies and priorities in amyotrophic lateral sclerosis. Lancet Neurol (2013) 2.52
Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A (2004) 2.46
The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain (2012) 2.33
Unraveling the regulatory mechanisms underlying tissue-dependent genetic variation of gene expression. PLoS Genet (2012) 2.29
The crucial role of Campylobacter jejuni genes in anti-ganglioside antibody induction in Guillain-Barre syndrome. J Clin Invest (2004) 2.25
The genetics and neuropathology of amyotrophic lateral sclerosis. Acta Neuropathol (2012) 2.25
A long-term prospective study of the natural course of sporadic adult-onset lower motor neuron syndromes. Arch Neurol (2009) 2.17
CD27 deficiency is associated with combined immunodeficiency and persistent symptomatic EBV viremia. J Allergy Clin Immunol (2011) 2.10
Population based epidemiology of amyotrophic lateral sclerosis using capture-recapture methodology. J Neurol Neurosurg Psychiatry (2011) 2.08
Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol (2011) 2.08
Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature (2012) 2.08
Is the Frontal Assessment Battery reliable in ALS patients? Amyotroph Lateral Scler Frontotemporal Degener (2012) 2.06
Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A (2009) 2.03
Residual fatigue in Guillain-Barre syndrome is related to axonal loss. Neurology (2013) 2.01
The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol (2004) 1.96
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. Lancet Neurol (2013) 1.91
Susceptibility loci for intracranial aneurysm in European and Japanese populations. Nat Genet (2008) 1.90
Multifocal motor neuropathy. Lancet Neurol (2005) 1.88
Genome-wide association study of intracranial aneurysm identifies three new risk loci. Nat Genet (2010) 1.86
Lifetime physical activity and the risk of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry (2013) 1.86
Weighted gene co-expression network analysis of the peripheral blood from Amyotrophic Lateral Sclerosis patients. BMC Genomics (2009) 1.72
Peripheral nerve involvement in spinocerebellar ataxias. Arch Neurol (2004) 1.72
Genetic analysis of DNA methylation and gene expression levels in whole blood of healthy human subjects. BMC Genomics (2012) 1.70
The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener (2013) 1.68
Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol (2009) 1.67
Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic inflammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial. Lancet Neurol (2010) 1.63
Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases. Neurology (2012) 1.62
Guillain-Barré syndrome subtypes related to Campylobacter infection. J Neurol Neurosurg Psychiatry (2011) 1.62
Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet (2012) 1.62
Structural characterization of Campylobacter jejuni lipooligosaccharide outer cores associated with Guillain-Barre and Miller Fisher syndromes. Infect Immun (2007) 1.60
European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet (2011) 1.58
Serum IgG levels in IV immunoglobulin treated chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry (2013) 1.57
Genome-wide association analyses in Han Chinese identify two new susceptibility loci for amyotrophic lateral sclerosis. Nat Genet (2013) 1.57
The H1069Q mutation in ATP7B is associated with late and neurologic presentation in Wilson disease: results of a meta-analysis. J Hepatol (2004) 1.49
IVIG treatment and prognosis in Guillain-Barré syndrome. J Clin Immunol (2010) 1.46
Variants of the elongator protein 3 (ELP3) gene are associated with motor neuron degeneration. Hum Mol Genet (2008) 1.46
Effect of non-invasive ventilation on survival, quality of life, respiratory function and cognition: a review of the literature. Amyotroph Lateral Scler (2006) 1.46
Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Ann Neurol (2011) 1.45
Physician-assisted death: dying with dignity? Lancet Neurol (2003) 1.44
Disease course of Charcot-Marie-Tooth disease type 2: a 5-year follow-up study. Arch Neurol (2003) 1.42
A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol (2003) 1.39
Measurement of pneumococcal polysaccharide vaccine responses for immunodeficiency diagnostics: combined IgG responses compared to serotype specific IgG responses. J Clin Immunol (2013) 1.39
Evidence-based care in amyotrophic lateral sclerosis. Lancet Neurol (2006) 1.37
In tandem analysis of CLCN1 and SCN4A greatly enhances mutation detection in families with non-dystrophic myotonia. Eur J Hum Genet (2008) 1.34
Guillain-Barré syndrome associated with preceding hepatitis E virus infection. Neurology (2014) 1.33
Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol (2013) 1.32
Motor network degeneration in amyotrophic lateral sclerosis: a structural and functional connectivity study. PLoS One (2010) 1.30
Detection, imputation, and association analysis of small deletions and null alleles on oligonucleotide arrays. Am J Hum Genet (2008) 1.27
Multifocal motor neuropathy: diagnosis, pathogenesis and treatment strategies. Nat Rev Neurol (2011) 1.25
Gene-network analysis identifies susceptibility genes related to glycobiology in autism. PLoS One (2009) 1.23